Intelligent Bio Solutions Inc (INBS)

$INBS started buying back with a small position. It’s undervalued and will add in a month either way.

Looks like volume & momentum could be shifting in to ASTC! Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $MGIH $INBS $TOP $BETR `

$INBS in it for the rally!

$INBS Ja, kauft IVDA, und heute Abend fällt es wieder, oder spätestens morgen....wie INBS (siehe Februar 2024) und dann seit ihr dort gefangen und wartet auf irgendetwas, was nie wieder passieren wird.

$INBS … so now it hit the new all time low today after the last resplit 😉I am looking sideways and will wait 👀

$INBS oh happy day🥰

$INBS NEED U SHORTLY

Intelligent Bio Solutions Inc. (NASDAQ: $INBS) provided an updated timeline toward anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. Intelligent Bio Solutions is a B2i Digital Featured company. View INBS’s comprehensive profile at https://b2idigital.com/intelligent-bio-solutions. Following recent feedback from the U.S. Food and Drug Administration (FDA), INBS has established a pathway to gather additional supporting data to strengthen its new 510(k) submission. The company announced several developments: • Clinical studies will begin before year-end to further validate the drug screening system, with completion expected in H1 2026 • FDA 510(k) clearance is anticipated in the second half of 2026 • The technology has achieved strong international traction with over 450 accounts across 24 countries and 18 distribution partners • Commercial operations continue to expand outside the U.S., while the company works toward U.S. entry beyond the Forensic Use Only market Peter Passaris, Vice President of Product Development at Intelligent Bio Solutions, noted: “We have a clear and achievable timeline for resubmitting our 510(k) application. The additional clinical data we are generating will supplement existing data and strengthen our package. We are committed to bringing our innovative technology to the U.S. market, while continuing to focus on the growth of the overall business.” The Intelligent Fingerprinting Drug Screening System screens for opiates, cocaine, methamphetamine, and cannabis through fingerprint sweat analysis, with sample collection in seconds and results in under ten minutes. Current international customer segments include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. See the full release at: https://investors.ibs.inc/news/news-details/2025/Intelligent-Bio-Solutions-Advances-Preparations-and-Provides-Updated-Timeline-for-Anticipated-FDA-510k-Submission-and-Clearance/default.aspx. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat-based testing worldwide. The company’s non-invasive, patented technology delivers results in under ten minutes and now supports more than 450 accounts across 24 countries in the workplace safety, law enforcement, drug treatment, and forensics markets. Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli MBus, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at [email protected], KCSA Strategic Communications. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted INBS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of INBS or any security, and it is not intended to offer any opinion on INBS as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$INBS This stock seems to be very promising, but when looking at the 5yr chart, it is concerning to see that it has consistently and continently just dropped to lower and lower prices. Why should one expect for this to stop dropping now?

$INBS Yes, very frustrating to get delayed again. But those who sold helped others average down or enter at a solid base SP. This technology is already in use worldwide and generating revenue. Distribution agreements are in place. Novel technology in the US has numerous FDA hurdles to overcome (made worse with staffing cuts and politics). So no to short term gains, but yes to potential long term gains. If dilution needed to fund these studies, so be it. The float is already low for a biotech company. I worry more about reverse splits. The market for drug screening is massive and permanent. This technology also has recurring revenue from cartridge sales (so not a one and done sale). So 10% of the float exchanged hands yesterday. Most of us are not in the money at this current SP. But a loss only occurs when you sell. No vision? Then sell. My cataracts were fixed already. I have vision and am not selling.